

In order to provide our readers with timely access to new content, papers accepted by the American Journal of Tropical Medicine and Hygiene are posted online ahead of print publication. Papers that have been accepted for publication are peer-reviewed and copy edited but do not incorporate all corrections or constitute the final versions that will appear in the Journal. Final, corrected papers will be published online concurrent with the release of the print issue.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

VENKATESAN AND OTHERS

PARASITE GENES AND RESISTANCE TO AL AND ASAQ

Polymorphisms in *Plasmodium falciparum* Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for *P. falciparum* Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine

Meera Venkatesan, Nahla B. Gadalla, Kasia Stepniewska, Prabin Dahal, Christian Nsanzabana, Clarissa Moriera, Ric N. Price, Andreas Mårtensson, Philip J. Rosenthal, Grant Dorsey, Colin J. Sutherland, Philippe Guérin, Timothy M. E. Davis, Didier Ménard, Ishag Adam, George Ademowo, Cesar Arze, Frederick N. Baliraine, Nicole Berens-Riha, Anders Björkman, Steffen Borrmann, Francesco Checchi, Meghna Desai Mehul Dhorda, Abdoulaye A. Djimdé, Badria B. El-Sayed, Teferi Eshetu, Frederick Eyase, Catherine Falade, Jean-François Faucher, Gabrielle Fröberg, Anastasia Grivoyannis, Sally Hamour, Sandrine Houzé, Jacob Johnson, Erasmus Kamugisha, Simon Kariuki, Jean-René Kiechel, Fred Kironde, Poul-Erik Kofoed Jacques LeBras, Maja Malmberg, Leah Mwai, Billy Ngasala, Francois Nosten, Samuel L. Nsoby, Alexis Nzila Mary Oguike, Sabina Dahlström Otienoburu, Bernhards Ogutu, Jean-Bosco Ouédraogo, Patrice Piola, Lars Rombo, Birgit Schramm, A. Fabrice Somé, Julie Thwing, Johan Ursing, Rina P. M. Wong, Ahmed Zeynudin, Issaka Zongo, Christopher V. Plowe, and Carol Hopkins Sibley*

WorldWide Antimalarial Resistance Network Molecular Module, Howard Hughes Medical Institute/Center for Vaccine Development, and Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; Department of Epidemiology, Tropical Medicine Research Institute, Khartoum, Sudan; World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom; Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia; Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Stockholm, Sweden; Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, University of California, San Francisco, San Francisco, California; Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; School of Medicine and Pharmacology, The University of Western Australia, Fremantle Hospital, Nedlands, Western Australia, Australia; Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia; Faculty of Medicine, University of Khartoum, Khartoum, Sudan; Institute for Advanced Medical Research and Training, College of Medicine, and Department of Pharmacology and Therapeutics, University of Ibadan; Ibadan, Nigeria; Department of Biology, LeTourneau University, Longview, Texas; Department of Infectious Diseases and Tropical Medicine, Ludwig Maximilians University, Munich, Germany; Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya; Department of Microbiology, Magdeburg University School of Medicine, Magdeburg, Germany; Save the Children, Paris, France; Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia; Epicentre Uganda Research Base, Mbarara, Uganda; Malaria Research and Training Centre, Faculty of Pharmacy, University of Science, Techniques and Technologies of Bamako, Bamako, Mali; Department of Medical Laboratory Sciences and Pathology, Medical Parasitology Unit, Jimma University, Jimma, Ethiopia; Global Emerging Infections System, U.S. Army Research Unit-Kenya Walter Reed/Kenya Medical Research Institute Project, Kisumu, Kenya; Department of Infectious Diseases, University Medical Center, Besançon, France; Mère et Enfant Face aux Infections Tropicales, Institut de Recherche pour le Développement, Paris, France; Department of Medicine, Division of Emergency Medicine, and Department of Genome Sciences, University of Washington, Seattle, Washington; University College London Centre for Nephrology, Royal Free Hospital, London, United Kingdom; Laboratory of Parasitology, Malaria National Reference Centre, Assistance Publique–Hôpitaux de Paris, Bichat Hospital, Paris France; PRES Sorbonne Paris Cité, Faculté de Pharmacie, Université Paris Descartes, Paris, France; United States Army Medical Research Unit-Kenya, Nairobi, Kenya; Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania; Malaria Branch, Kenya Medical Research Institute/Centers for Disease Control and Prevention, Kisumu, Kenya; Drugs for Neglected Diseases initiative, Geneva, Switzerland; Makerere University College of Health Sciences, Kampala, Uganda; St. Augustine International University, Kampala, Uganda; Projecto de Saude

de Bandim, INDEPTH Network, Bissau, Guinea-Bissau; Division of Translational Therapeutics, Department of Paediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Department of Parasitology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Department of Pathology, School of Biomedical Science, Makerere University College of Health Sciences, Kampala, Uganda; Department of Biology, King Fahd University of Petroleum and Minerals, Dhahran, Saudi Arabia; Worldwide Antimalarial Resistance Network, Institut de Médecine et d'Epidémiologie Appliquée, Bichât-C. Bernard Hospital, Paris, France; Institut de Recherche en Sciences de la Santé, Centre Muraz, Bobo-Dioulasso, Burkina Faso; Institut Pasteur du Madagascar, Antananarivo, Madagascar; Epicentre, Paris, France

* Address correspondence to Carol Hopkins Sibley, Department of Genome Sciences, University of Washington, Box 355586, Seattle, WA 98195. E-mail: sibley@u.washington.edu

Abstract.

Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the *Plasmodium falciparum* chloroquine resistance transporter (*pfcr*) and *P. falciparum* multidrug resistance 1 (*pfmdr1*) genes are associated with decreased sensitivity to amodiaquine and lumefantrine, but effects of these polymorphisms on therapeutic responses to artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) have not been clearly defined. Individual patient data from 31 clinical trials were harmonized and pooled by using standardized methods from the WorldWide Antimalarial Resistance Network. Data for more than 7,000 patients were analyzed to assess relationships between parasite polymorphisms in *pfcr* and *pfmdr1* and clinically relevant outcomes after treatment with AL or ASAQ. Presence of the *pfmdr1* gene N86 (adjusted hazards ratio = 4.74, 95% confidence interval = 2.29–9.78, $P < 0.001$) and increased *pfmdr1* copy number (adjusted hazards ratio = 6.52, 95% confidence interval = 2.36–17.97, $P < 0.001$) were significant independent risk factors for recrudescence in patients treated with AL. AL and ASAQ exerted opposing selective effects on single-nucleotide polymorphisms in *pfcr* and *pfmdr1*. Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least *pfcr* K76T and *pfmdr1* N86Y should now be routine.

INTRODUCTION

Recent successes in malaria control have depended on the use of highly efficacious artemisinin combination therapies (ACTs) for first-line treatment of uncomplicated *Plasmodium falciparum* malaria. Adequate clinical and parasitologic cure by ACTs relies on the rapid reduction in parasite biomass by the potent, short-acting artemisinin component^{1–3} and the subsequent elimination of residual parasites by the longer-acting partner drug. The two most commonly used ACTs worldwide are artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ).⁴ Polymerase chain reaction (PCR)–adjusted efficacy for both combinations remains high in most regions.^{5–7} However, there have been some reports of decreasing AL cure rates in Africa^{8–11} and Asia,¹² and reports of high levels of treatment failures of ASAQ.^{13–18} Resistance to ACT partner drugs has historically manifested before that of artemisinins, whose short half-lives result in the exposure of residual parasites to sub-therapeutic levels of the partner drug alone. Response to the partner drug is therefore a key component of overall ACT efficacy.

Mutations in the gene encoding the *P. falciparum* chloroquine resistance transporter (*pfcr*) are associated with chloroquine resistance¹⁹; a change from lysine to threonine at codon 76 in *pfcr* predicts responses of parasites to chloroquine.^{20,21} In the presence of *pfcr* 76T, chloroquine resistance is modulated by point mutations in the gene that encodes the *P. falciparum* multidrug resistance transporter 1 (*pfmdr1*), primarily at codon 86^{22,23} and also by mutations at positions 1034, 1042, and 1246.²⁴ Decreased susceptibility to lumefantrine has been linked to polymorphisms in these two genes.^{25–35} Increased *pfmdr1* copy number, which confers resistance to mefloquine,³⁶ has also been associated with reduced susceptibility to lumefantrine.^{37–40}

Studies of amodiaquine have demonstrated reduced *in vivo* response^{41–43} and increased 50% inhibitory concentration values *in vitro*, in association with the presence of *pfmdr1* 86Y and *pfcr* 76T alleles.^{44,45} Selection of these alleles in recurrent parasites after treatment with amodiaquine alone or in combination with artesunate has been observed in a number of studies.^{28,46–51} It has also been suggested that parasites that carry chloroquine-resistant *pfmdr1* alleles may be more susceptible to artesunate in classical *in vitro* assays,^{24,52} an effect that could counteract the increased risk of amodiaquine failure when these drugs are combined in ASAQ.

Currently, AL and ASAQ retain high clinical efficacy with few recrudescence infections, and individual studies generally lack sufficient statistical power to assess the association between parasite genotypes and outcomes of clinical treatment. Such an assessment is a critical step in validating molecular changes in parasite populations as useful markers of early signs of changing parasite susceptibility to lumefantrine or amodiaquine. To overcome these challenges, individual patient data on *in vivo* antimalarial efficacy and molecular markers of *P. falciparum* from 31 clinical trials were standardized, pooled, and > 7,000 patient responses were analyzed to determine whether patients infected with parasites that carry these polymorphisms are at increased risk of treatment failure. This large data set also provided the opportunity to examine the effects of AL and ASAQ treatment on selection in parasites of particular alleles of *pfcr* and *pfmdr1*.

METHODS

Selection and inclusion of data.

Prospective clinical efficacy studies of *P. falciparum* treatment with AL (six-dose regimen) or ASAQ (three-day fixed dose or loose/co-blistered regimen) with a minimum of 28 days of follow-up and genotyping of *pfcr* and/or *pfmdr1* were sought for the analysis. Studies were identified by a systematic PubMed literature review using the search terms (artesunate AND amodiaquine) OR (artemether AND lumefantrine) OR (ACT) AND (*pfmdr1* OR *pfcr*). Abstracts and text were screened to determine whether inclusion criteria were met. Unpublished datasets were also solicited and included in the analysis. Individual anonymized patient data including baseline characteristics, drug intake, parasite density and temperature were collected. All but one study included parasite genotyping to identify recrudescence infections of *P. falciparum*, and all studies assessed the presence of *pfcr* and/or *pfmdr1* polymorphisms (single nucleotide polymorphisms (SNPs) and copy number variation) in parasites isolated from patients on day 0. Multiplicity of infection and molecular resistance marker data from other days including the day of microscopic recurrent parasitemia were included but were not a prerequisite for study inclusion. Metadata on study location, study design, drugs, and dosing regimens were also gathered. A schematic of the patient numbers and overall flow of the study is shown in Figure 1.

Data curation and generation of variables.

All data sets were uploaded to the WorldWide Antimalarial Resistance Network repository and standardized by using the WorldWide Antimalarial Resistance Network Data Management and Statistical Analysis Plans (DMSAP).^{53,54} Outcome status and censoring were defined according to the Clinical DMSAP.⁵³ Parasites that recurred within the follow-up period were classified using World Health Organization guidelines⁵⁵: microscopically detected infections during follow-up were classified as recurrent; recurrent infections sharing with blood samples taken at day 0 PCR bands in polymorphic merozoite antigens or microsatellite fragment sizes were classified as recrudescence, and recurrent infections not sharing PCR bands or microsatellite fragment sizes with blood samples taken at day 0 were classified as re-infections (new infections). Molecular markers were coded as either single or mixed allele genotypes in the case of SNPs and as mean copy number per sample for copy number polymorphisms. Multi-SNP haplotypes were reconstructed as described in the Molecular DMSAP.^{56,57}

Statistical analysis.

All statistical analyses were conducted by using Stata 11 (StataCorp LP, College Station, TX). The primary endpoint was clinical efficacy, defined as the PCR-adjusted risk of *P. falciparum* recrudescence infections. The cumulative risk of recrudescence at day 28 and day 42 was computed by using survival analysis (Kaplan-Meier estimates [K-M]). Comparisons of K-M survival curves were performed by using log rank tests stratified by study sites.

Multivariable analysis of risk factors associated with PCR-adjusted recrudescence was conducted by using Cox proportional hazards regression models with shared frailty parameters to adjust for site-specific effects. The risk factors that affect the clinical efficacy of AL and ASAQ have been intensively studied in

pooled analyses of both ACTs. Sixty-two studies with 14,651 patients treated with AL and 39 studies with 8,337 patients treated with ASAQ were analyzed; these full analyses have been submitted for publication. The univariable and multivariable risk factors identified in those studies are shown in Supplemental Tables 1 and 2. Clinical covariates in the current study were included based on the previous analyses as follows: (lumefantrine or amodiaquine dose, enrolment parasitemia, age category, and ASAQ fixed or co-blistered versus loose formulation (Table 1). Each molecular marker was then added to the model. The proportional hazard assumption was tested based on Schoenfeld residuals of Schoenfeld.⁵⁸ In the case of non-proportionality, interactions with a categorized time variable based on clinical follow-up intervals (< day 14, days 14–21, 21–28, and > day 28) were used to account for changing effects over time, and neighboring windows with similar effects of genetic covariates as determined by Wald test were merged. Finally, other covariates (transmission intensity, region of sample origin, dose supervision, and fat intake) were included in the model if they improved model fit based on the likelihood ratio test. Multiplicity of infection was only available for 197 and 141 AL and ASAQ patients, respectively, and was excluded from further analysis. The final model was then used to estimate the adjusted hazard ratio for recrudescence in patients who carried parasites with resistant versus sensitive genotypes on day 0. The assumption of proportional hazards was tested separately for the individual covariates in the final multivariable model, and any violations were reported.

In patients who had recurrent parasitemia on or before day 42, changes in *pfprt* and *pfmdr1* alleles between pre-treatment and post-treatment matched pairs of samples was compared by using McNemar's test. Changes in genotype, rather than presence of a particular allele, were compared between matched pairs to ensure that differences reflected selection rather than underlying differences in allele frequencies among populations. The effect of markers present at the time of recurrence on median time to PCR-adjusted re-infection (new infection) was investigated by using the Wilcoxon Mann-Whitney U test. Competing risk analysis⁵⁹ was used to estimate cumulative incidence of PCR-adjusted re-infections with specific genotypes, where recrudescence and re-infections with other genotypes were treated as competing events.

The number of molecular markers used to distinguish recrudescence from re-infection varied from one to three or more loci. The effect of the number of loci genotyped on outcome classification was investigated in a regression model of predictors of recrudescence within all recurrences. No effect of this variable was observed on the number of recrudescence infections identified among recurrences in univariable or multivariable analysis, it was not further investigated.

RESULTS

Individual patient and linked parasite genotype data from 31 studies were available (Supplemental Table 3). Data from 7,249 patients who were treated with AL (5,003) or ASAQ (2,246) were included in the analysis. Twenty two studies were published, representing 91% of all published clinical data on AL and ASAQ in which *pfprt* or *pfmdr1* genotypes were determined. Baseline characteristics for patients treated with AL or ASAQ are shown in Supplemental Table 4.

Clinical efficacy of AL and ASAQ.

The estimates of efficacy (defined as risk of PCR-adjusted recrudescence) of AL and ASAQ are shown in Table 2. Of the 5,003 AL patients, 4,763 were followed-up for at least one day and were included in the analysis. Similarly, of the 2,246 ASAQ patients, 2,099 were included. In total, 1,107 patients had recurrent parasitemia after treatment with AL, of 188 (18%) were classified by PCR as having recrudescence infections. The corresponding figures for ASAQ were 484 patients had recurrent parasitemia and 58 (12%) were confirmed as having recrudescence infections. The overall clinical efficacy at day 42 was 94.8% (95% confidence interval [CI] = 94–95.5%) in patients treated with AL and 95.1% (95% CI = 92.3–96.7%) in patients treated with ASAQ (Table 2). The proportion of adequate clinical and parasitologic response of ASAQ was significantly higher for the fixed dose and co-blistered tablets (97.0%, 95% CI = 94.4–98.4%) compared with the loose formulation (93.0%, [95% CI = 89.2–95.6] ($P = 0.003$).

Baseline prevalence of genetic markers associated with resistance.

The baseline prevalence of SNPs in *pfprt* and *pfmdr1* was determined, but not all SNPs were available for all isolates. The most frequently analyzed SNPs were position 76 in *pfprt* determined for 3,640 patients and position 86 in *pfmdr1* for 3,580 patients, with the complete haplotype of positions 72–76 in *pfprt*, *pfmdr1* copy number, and SNPs at positions *pfmdr1* 184, 1034, 1042, and 1246 available in a subset of patients (Table 3).

The prevalence of *pfprt* and *pfmdr1* alleles varied by region (Table 3). The *pfprt* 76T allele (all in the SVMNT haplotype) was almost fixed at 96.4% (81/84) in isolates from Asia (Thailand) and Oceania (Papua New Guinea). In Africa, the only resistant haplotype observed was the CVIET allele. The 76T allele predominated: 67.6% (1,155/1,708) in East Africa and 73.3% (1,354/1,848) in West Africa (Table 3). Amplification of *pfmdr1* was seen in 50% (88/176) of isolates from Asia examined for this genotype, but only in 2.4% (16/659) of isolates from Africa. *Pfmdr1* 86Y was found in 29.2% (66/226) of isolates from Asia/Oceania; in contrast, the 86Y allele was present in 44.1% (896/2,033) of isolates from East Africa and 34.3% (453/1,321) of isolates from West Africa.

The SNPs at positions 184 and 1246 showed similar patterns, with *pfmdr1* Y184 and D1246 predominating in all three regions (Table 3). Almost all isolates examined carried the *pfmdr1* S1034 (760/844) and N1042 (1,053/1,064).

Parasite genotypes as risk factors for recrudescence infection.

After controlling for age, baseline parasite density, and total lumefantrine dose (Table 1), the presence of parasites in the initial infection that carried *pfmdr1* N86 (alone or a mixed infection with *pfmdr1* 86Y) was a significant risk factor for recrudescence infection occurring between days 14 and 28 after AL treatment (adjusted hazards ratio [AHR] = 4.74, 95% CI = 2.29–9.78, $P < 0.001$) (Table 4 and Figure 2A). Region of sample origin was not included as a covariate in the model because it violated the assumption of proportional hazards. The risk associated with presence of *pfmdr1* N86 remained significant when excluding infections with multiple copies of *pfmdr1* (AHR = 3.93, 95% CI = 1.90–8.94, $P < 0.001$). The region of sample origin interacted significantly with *pfmdr1* N86, showing that the marker had a larger effect in Asia (AHR = 14.06, 95% CI = 4.52–43.74, $P < 0.001$) than in Africa (AHR = 3.72, 95% CI = 1.77–7.79, $P = 0.001$). However, this interaction violated the proportional hazards assumption since there were so few samples in Africa that had multiple copies of *pfmdr1*, and this variable was excluded from the final model.

The presence of more than one copy of *pfmdr1* was a significant risk factor for recrudescence occurring between days 14 and 21 after AL treatment (AHR = 5.81, 95% CI = 2.38–14.21, $P < 0.001$) (Figure 2B). When the effect of region of origin was added to the model, patients with parasites carrying multiple copy numbers of *pfmdr1* were associated with an increased risk of recrudescence before day 14 (AHR = 83.56, 95% CI = 7.43–939.70, $P < 0.001$) as well as between days 14 and 21 (AHR = 18.54 (95% CI = 7.61–45.19, $P < 0.001$) (Table 4). The interaction of region of origin with *pfmdr1* copy number could not be investigated because of insufficient multicopy samples from Africa in the model.

When *pfmdr1* N86 and *pfmdr1* copy number were included in the same model, region of sample origin was no longer a significantly predictive covariate in the multivariable analysis or as an interaction term with either genotype. Both markers remained as significant predictors of recrudescence infection, between days 14 and 28 for *pfmdr1* N86 (AHR = 5.98, 95% CI = 1.68–21.36, $P = 0.006$) and days 14 and 21 for multiple copies of *pfmdr1* (AHR = 6.52, 95% CI = 2.36–17.97, $P < 0.001$); Table 4)

No association was observed between the *pfmdr1* 184, *pfmdr1* 1246, and *pfprt* polymorphisms and recrudescence infections after AL treatment. The risk for parasites with the *pfmdr1* N86 + D1246 haplotype is not reported here because it represents a subset of the *pfmdr1* N86 sample set (of the samples genotyped for both SNPs, all but 17 samples with *pfmdr1* N86 also had D1246). For patients treated with ASAQ, none of the analyzed *pfprt* or *pfmdr1* parasite genotypes were significant risk factors for recrudescence infections in the multivariable analysis.

Post-treatment selection of genetic markers associated with resistance.

To examine changes in the genotypes of parasites after drug treatment, we compared the prevalence of *pfmdr1* and *pfcr1* alleles in paired isolates from the initial and the recurrent parasites in the subset of patients in whom parasites recurred during the 42 day follow-up period. Post-treatment changes among specific genotypes are shown in Table 5 for all recurrent infections. Significant selection of *pfcr1* K76, *pfmdr1* N86 occurred in recrudescence and re-infecting parasites after AL treatment. Selection of *pfmdr1* 184F and D1246 alleles was also observed in the recurrent parasites and *pfmdr1* D1246 in those that reinfected patients after treatment. Selection of single or multiple copies of *pfmdr1* was not observed in any of the groups (Table 5). *Pfmdr1* 86Y and 1246Y were significantly selected in recurrent and re-infections after treatment with ASAQ (Table 5).

Median time to re-infection.

The genotype of parasites at the time of re-infection provides another metric of their susceptibility to a drug. This analysis indicated that in patients treated with AL, re-infecting parasites carrying *pfmdr1* N86, *pfmdr1* D1246, or *pfcr1* K76 alleles appeared earlier than those carrying *pfmdr1* 86Y, *pfmdr1* 1246Y, or *pfcr1* 76T (Figure 3A). Correspondingly, in patients treated with AL, parasites carrying *pfmdr1* N86 had a median time to re-infection of 28 days (interquartile range = 21–35 days) compared with 35 days (interquartile range = 28–42 days) for those with *pfmdr1* 86Y ($P < 0.001$). Similar differences in the time to re-infection were observed for patients infected with parasites that carried the *pfmdr1* 184F ($P = 0.008$) or *pfcr1* K76 alleles ($P = 0.001$) compared with *pfmdr1* Y184 or *pfcr1* 76T.

In contrast, in patients treated with ASAQ, parasites carrying *pfmdr1* 86Y, *pfmdr1* 1246Y, or *pfcr1* 76T appeared earlier after treatment than those carrying *pfmdr1* N86, *pfmdr1* D1246 or *pfcr1* K76 (Figure 3B). Parasites with *pfcr1* 76T had a median reinfection day of 28 (interquartile range = 21–35) compared with day 37.5 (interquartile range = 28–42) for those carrying K76 ($P = 0.053$) and those with *pfmdr1* 1246Y re-infected on a median day of 21 (interquartile range = 21–28) compared with day 28 (interquartile range = 21–35) for those with D1246 ($P = 0.001$).

DISCUSSION

This pooled analysis of data from 31 clinical studies shows clearly that the genotypes of infecting parasites influence the outcome of AL treatment. Patients infected with parasites that carried the *pfmdr1* N86 allele or increased *pfmdr1* copy number were at significantly greater risk of treatment failure than those whose parasites carried the 86Y allele or a single copy of *pfmdr1*. Analysis of the clinical outcomes after treatment with ASAQ did not link a particular genotype with treatment failure in this smaller data set. However, it did show clear evidence of selection of particular parasite genotypes. Our findings are consistent with those of previous molecular studies in which changes in the prevalence of particular alleles of *pfcr1* or *pfmdr1* have been documented in response to introduction or increased use of lumefantrine^{25–35} or amodiaquine.^{15,28,40–51}

Our observation that parasites with the *pfmdr1* N86, D1246, and *pfcr1* K76 alleles re-infected patients earlier after AL treatment, and parasites carrying the *pfmdr1* 86Y, 1246Y, and *pfcr1* 76T alleles re-infected patients earlier after ASAQ is also congruent with the molecular studies. These differences suggest that parasites with these genotypes can withstand higher drug concentrations compared with parasites that carry the alternative alleles. Recently, Malmberg and others³³ demonstrated this effect quantitatively. After AL treatment, parasites with the *pfmdr1* N86/184F/D1246 haplotype were able to re-infect patients whose lumefantrine blood concentrations were 15-fold higher than was the case for parasites carrying the 86Y/Y184/1246Y haplotype,³³ providing a potential pharmacologic explanation for the molecular findings. Together, these observations suggest that monitoring shifts to earlier time of re-infection could provide a relatively simple warning of decreasing susceptibility to these drugs, especially if combined with timed measurement of drug concentrations in patients' blood.

In Southeast Asia, parasites with increased *pfmdr1* copy number are common in areas where mefloquine has been intensively deployed,³⁶ and almost half of the samples in our data set from that

region had at least two copies of the gene. Increased *pfmdr1* copy number was rarely observed in our large sample of isolates from Africa, populations that have had little exposure to mefloquine. Lumefantrine has a shorter half-life in patients than mefloquine,⁶⁰ and may not exert an equivalently strong selection for copy number increase. However, in areas where mefloquine is being introduced, close attention to *pfmdr1* copy number is clearly warranted. A recent report of parasites in Ghana with increased *pfmdr1* copy number underscores the importance of including this parameter in molecular surveillance.⁶¹

This study supported the conclusion that parasites with increased copy number of *pfmdr1* are also less sensitive to lumefantrine.^{37–40} In Southeast Asia, the amplified alleles almost always carried the N86 allele of *pfmdr1*.^{34,36,62} However, this was not the case in the few parasites from Africa in our data set that did have an increased copy number³¹ so either of the N86Y alleles of *pfmdr1* can apparently be amplified. It is also important to note that increased copy number and the presence of the *pfmdr1* N86 allele were independent risk factors for treatment failure in our analysis.

The evidence of strong selection of particular alleles by both drugs in recurrent parasites, coupled with our observation that particular parasite genotypes increase risk of treatment failure, demonstrates that tracking these molecular markers can signal early decreases in susceptibility to lumefantrine or amodiaquine. Both alleles of *pfmdr1* N86Y, Y184F, and D1246Y are common in *P. falciparum* populations in Africa, and *pfcr1* K76 has increased in prevalence in recent years. Thus, changes in the prevalence of these alleles can be a sensitive indicator of selection of parasite populations by AL and ASAQ. In turn, decreasing efficacy of these partner drugs exposes the artemether or artesunate component of the ACT to selective pressure and could facilitate emergence of new foci of resistance to artemisinin, as observed in the Mekong region. The recent identification of a marker correlated with slow response to artemisinin,⁶³ will also enable molecular assessment of this trend.

Application of these molecular tools is increasingly feasible in the context of clinical trials and in community surveys of populations where AL or ASAQ are heavily used. These approaches can offer cost-effective methods that detect evidence of declines in parasite susceptibility far earlier than before, enabling detailed studies of clinical responses to the drugs in areas of concern. This two-stage approach can provide an opportunity for policy makers to manage emerging threats of resistance before clinical failure of a drug is manifest and preserve the useful therapeutic life of these valuable antimalarial drugs for as long as possible.

Finally, these results suggest that AL and ASAQ interact with the proteins encoded by *pfcr1* and *pfmdr1*, but the two drugs select alternative alleles. Two recent publications have also demonstrated that piperaquine exerts selection pressure on these genes in the same direction as amodiaquine, suggesting that the newer ACT, dihydroartemisinin-piperaquine could also function as a counterweight to lumefantrine.^{64,65} This opposing selection of parasite genotypes by the partner drugs could influence the choice of an ACT in regions with different patterns of *pfcr1* and *pfmdr1* polymorphisms. For example, if a particular allele is rapidly increasing under intensive use of AL, introduction of AQ or piperaquine might be introduced to counteract that trend. Concurrent use of two ACTs that exert opposing selective pressures on recurrent parasites could provide a counterbalance and prevent strong directional selection in *pfcr1* and *pfmdr1*, maintaining the overall efficacy of AL and ASAQ for a long period. Despite logistical challenges, the simultaneous use of multiple first line therapies is supported by mathematical models,^{66–68} and concurrent availability of AL and ASAQ, as implemented in some countries in West Africa⁴ may provide a practical means to test this strategy directly.

Received January 14, 2014.

Accepted for publication April 22, 2014.

Note: Supplemental tables appear at www.ajtmh.org.

Financial support: The WorldWide Antimalarial Resistance Network is supported by the Bill and Melinda Gates Foundation.

Disclaimer: The opinions and assertions contained herein are the personal opinions of authors and are not to be construed as reflecting the views of the U.S. Army Medical Research Unit-Kenya or the U.S. Department of Defense.

Authors' addresses: Meera Venkatesan and Christopher V. Plowe, WorldWide Antimalarial Resistance Network Molecular Module and Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD. Nahla B. Gadalla National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, and Department of Epidemiology, Tropical Medicine Research Institute, Khartoum, Sudan. Kasia Stepniewska, Prabin Dahal, Christian Nsanzabana, and Clarissa Moriera, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. Ric N. Price, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, and Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia. Andreas Mårtensson, Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Stockholm, Sweden, and Global Health, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden. Philip J. Rosenthal and Grant Dorsey, Department of Medicine, University of California, San Francisco, San Francisco, CA. Colin J. Sutherland and Mary Oguike, Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. Philippe Guérin, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. Timothy M. E. Davis and Rina P. M. Wong, School of Medicine and Pharmacology, The University of Western Australia, Fremantle Hospital, Nedlands, Western Australia, Australia. Didier Ménard, Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia. Ishag Adam, Faculty of Medicine, University of Khartoum, Khartoum, Sudan. George Ademowo, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria. Cesar Arze, WorldWide Antimalarial Resistance Network Molecular Module and Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD. Frederick N. Baliraine, Department of Biology, LeTourneau University, Longview, TX. Nicole Berens-Riha, Department of Infectious Diseases and Tropical Medicine, Ludwig Maximilians University, Munich, Germany. Anders Björkman, Gabrielle Fröberg, Maja Malmberg, Lars Rombo, and Johan Ursing, Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Stockholm, Sweden. Steffen Borrmann, Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, and Department of Microbiology, Magdeburg University School of Medicine, Magdeburg, Germany. Francesco Checchi, Save the Children, Paris, France. Meghna Desai and Julie Thwing, Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA. Mehul Dhorda, WorldWide Antimalarial Resistance Network Molecular Module, University of Maryland School of Medicine, Baltimore, MD, and Epicentre Uganda Research Base, Mbarara, Uganda. Abdoulaye A. Djimdé, Malaria Research and Training Centre, Faculty of Pharmacy, University of Science, Techniques and Technologies of Bamako, Bamako, Mali. Badria B. El-Sayed, Department of Epidemiology, Tropical Medicine Research Institute, Khartoum, Sudan. Teferi Eshetu and Ahmed Zeynudin, Department of Medical Laboratory Sciences and Pathology, Medical Parasitology Unit, Jimma University, Jimma, Ethiopia. Frederick Eyase and Bernhards Ogotu, Global Emerging Infections System, U.S. Army Research Unit-Kenya Walter Reed/Kenya Medical Research Institute Project, Kisumu, Kenya. Catherine Falade, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria. Jean-François Faucher, Department of Infectious Diseases, University Medical Center, Besançon, France, and Institut de Recherche pour le Développement, Paris, France. Anastasia Grivoyannis, Department of Medicine, Division of Emergency Medicine, University of Washington, Seattle, WA. Sally Hamour, University College London Centre for Nephrology, Royal Free Hospital, London, United Kingdom. Sandrine Houzé and Jacques LeBras, Laboratory of Parasitology, Malaria National Reference Centre, Assistance Publique-Hôpitaux de Paris, Bichât Hospital, Paris France, Institut de Recherche pour le Développement, Mère et Enfant Face aux Infections Tropicales, Paris, France, and Faculté de Pharmacie, PRES Sorbonne Paris Cité, Université Paris Descartes, Paris, France. Jacob Johnson, U.S. Army Medical Research Unit-Kenya, Nairobi, Kenya. Erasmus Kamugisha, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania. Simon Kariuki, Malaria Branch, Kenya Medical Research Institute/Centers for Disease Control and Prevention, Kisumu, Kenya. Jean-René Kiechel, Drugs for Neglected Diseases Initiative, Geneva, Switzerland. Fred Kironde, Makerere University College of Health Sciences, Kampala, Uganda, and St. Augustine International University, Kampala, Uganda. Poul-Erik Kofoed, Projecto de Saude de Bandim, INDEPTH Network, Bissau, Guinea-Bissau. Leah Mwai, Division of Translational Therapeutics, Department of Paediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Billy Ngasala, Department of Parasitology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. Francois Nosten, Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, and Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Samuel L. Nsobya, Department of Pathology, School of Biomedical Science, Makerere University College of Health Sciences, Kampala, Uganda. Alexis Nzila, Department of Biology, King Fahd University of Petroleum and Minerals, Dhahran, Saudi Arabia. Sabina Dahlström Otienoburu, Worldwide Antimalarial Resistance Network, Institut de Médecine et d'Epidémiologie Appliquée, Bichât-C. Bernard Hospital, Paris, France. Jean-Bosco Ouédraogo, A. Fabrice Somé, and Issaka Zongo, Institut de Recherche en Sciences de la Santé, Centre Muraz, Bobo-Dioulasso, Burkina Faso. Patrice Piola, Institut Pasteur du Madagascar, Antananarivo, Madagascar. Birgit Schramm, Epicentre, Paris, France. Carol Hopkins Sibley, World Wide Antimalarial Resistance Network, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, and Department of Genome Sciences, University of Washington, Seattle, WA.

REFERENCES

- <jrn>1. Bethell DB, Teja-Isavadharm P, Cao XT, Pham TT, Ta TT, Tran TN, Nguyen TT, Pham TP, Kyle D, Day NP, White NJ, 1997. Pharmacokinetics of oral artesunate in children with moderately severe *Plasmodium falciparum* malaria. *Trans R Soc Trop Med Hyg* 91: 195–198.</jrn>
- <jrn>2. Na BK, Karbwang J, Thomas CG, Thanavibul A, Sukontason K, Ward SA, Edwards G, 1994. Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. *Br J Clin Pharmacol* 37: 249–253.</jrn>
- <jrn>3. White NJ, van VM, Ezzet F, 1999. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. *Clin Pharmacokinet* 37: 105–125.</jrn>
- <eref>4. World Health Organization, 2013. *World Malaria Report 2013*. Available at: http://www.who.int/malaria/publications/world_malaria_report_2013/report/en/. Accessed December 30, 2013.</eref>
- <jrn>5. Makanga M, Krudsood S, 2009. The clinical efficacy of artemether/lumefantrine (Coartem). *Malar J* 8 (Suppl 1): S5.</jrn>
- <jrn>6. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P, 2009. Artemisinin-based combination therapy for treating uncomplicated malaria. *Cochrane Database Syst Rev* CD007483.</jrn>
- <jrn>7. Stover KR, King ST, Robinson J, 2012. Artemether-lumefantrine: an option for malaria. *Ann Pharmacother* 46: 567–577.</jrn>
- <jrn>8. Mukhtar EA, Gadalla NB, El-Zaki SE, Mukhtar I, Mansour FA, Babiker A, El-Sayed BB, 2007. A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan. *Malar J* 6: 92.</jrn>
- <jrn>9. Siribie M, Diarra A, Tiono AB, Soulama I, Sirima SB, 2012. Efficacy of artemether-lumefantrine in the treatment of uncomplicated malaria in children living in a rural area of Burkina Faso in 2009. *Bull Soc Pathol Exot* 105: 202–207.</jrn>
- <jrn>10. Abuaku B, Duah N, Quaye L, Quashie N, Koram K, 2012. Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. *Malar J* 11: 388.</jrn>
- <jrn>11. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Martensson A, 2011. Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. *Malar J* 10: 64.</jrn>
- <jrn>12. Song J, Socheat D, Tan B, Seila S, Xu Y, Ou F, Sokunthea S, Sophorn L, Zhou C, Deng C, Wang Q, Li G, 2011. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. *Malar J* 10: 231.</jrn>
- <jrn>13. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ, 2005. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. *Lancet* 365: 1474–1480.</jrn>
- <jrn>14. Martensson A, Stromberg J, Sisowath C, Mselle MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Bjorkman A, 2005. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood *Plasmodium falciparum* malaria in Zanzibar, Tanzania. *Clin Infect Dis* 41: 1079–1086.</jrn>
- <jrn>15. Thwing JI, Odero CO, Odhiambo FO, Otieno KO, Kariuki S, Ord R, Roper C, McMorro M, Vulule J, Slutsker L, Newman RD, Hamel MJ, Desai M, 2009. *In-vivo* efficacy of amodiaquine-

artesunate in children with uncomplicated *Plasmodium falciparum* malaria in western Kenya. *Trop Med Int Health* 14: 294–300.</jrn>

- <jrn>16. Hamour S, Melaku Y, Keus K, Wambugu J, Atkin S, Montgomery J, Ford N, Hook C, Checchi F, 2005. Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. *Trans R Soc Trop Med Hyg* 99: 548–554.</jrn>
- <jrn>17. Swarthout TD, van den Broek IV, Kayembe G, Montgomery J, Pota H, Roper C, 2006. Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. *Trop Med Int Health* 11: 1503–1511.</jrn>
- <jrn>18. Rwagacondo CE, Karema C, Mugisha V, Erhart A, Dujardin JC, Van OC, Ringwald P, D'Alessandro U, 2004. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. *Trop Med Int Health* 9: 1091–1098.</jrn>
- <jrn>19. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE, 2000. Mutations in the *P. falciparum* digestive vacuole transmembrane protein *Pfcr* and evidence for their role in chloroquine resistance. *Mol Cell* 6: 861–871.</jrn>
- <jrn>20. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, 2001. A molecular marker for chloroquine-resistant *falciparum* malaria. *N Engl J Med* 344: 257–263.</jrn>
- <jrn>21. Djimde AA, Barger B, Kone A, Beavogui AH, Tekete M, Fofana B, Dara A, Maiga H, Dembele D, Toure S, Dama S, Ouologuem D, Sangare CP, Dolo A, Sogoba N, Nimaga K, Kone Y, Doumbo OK, 2010. A molecular map of chloroquine resistance in Mali. *FEMS Immunol Med Microbiol* 58: 113–118.</jrn>
- <jrn>22. Babiker HA, Pringle SJ, Abdel-Muhsin A, Mackinnon M, Hunt P, Walliker D, 2001. High-level chloroquine resistance in Sudanese isolates of *Plasmodium falciparum* is associated with mutations in the chloroquine resistance transporter gene *pfcr* and the multidrug resistance Gene *pfmdr1*. *J Infect Dis* 183: 1535–1538.</jrn>
- <jrn>23. Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T, Subramanian G, Aravind L, Cooper RA, Wootton JC, Xiong M, Su XZ, 2003. Multiple transporters associated with malaria parasite responses to chloroquine and quinine. *Mol Microbiol* 49: 977–989.</jrn>
- <jrn>24. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF, 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in *Plasmodium falciparum*. *Nature* 403: 906–909.</jrn>
- <jrn>25. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP, 2005. *In vivo* selection of *Plasmodium falciparum pfmdr1* 86N coding alleles by artemether-lumefantrine (Coartem). *J Infect Dis* 191: 1014–1017.</jrn>
- <jrn>26. Dokomajilar C, Nsoby SL, Greenhouse B, Rosenthal PJ, Dorsey G, 2006. Selection of *Plasmodium falciparum pfmdr1* alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. *Antimicrob Agents Chemother* 50: 1893–1895.</jrn>
- <jrn>27. Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, Bjorkman A, Krishna S, Gil JP, 2007. The role of *pfmdr1* in *Plasmodium falciparum* tolerance to artemether-lumefantrine in Africa. *Trop Med Int Health* 12: 736–742.</jrn>
- <jrn>28. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, Hallett RL, 2007. Amodiaquine and artemether-lumefantrine select distinct alleles of the *Plasmodium falciparum* *mdr1* gene in Tanzanian children treated for uncomplicated malaria. *Antimicrob Agents Chemother* 51: 991–997.</jrn>

- <jrn>29. Uhlemann AC, McGready R, Ashley EA, Brockman A, Singhasivanon P, Krishna S, White NJ, Nosten F, Price RN, 2007. Intrahost selection of *Plasmodium falciparum* *pfmdr1* alleles after antimalarial treatment on the northwestern border of Thailand. *J Infect Dis* 195: 134–141.</jrn>
- <jrn>30. Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouedraogo JB, Rosenthal PJ, 2010. Selection of known *Plasmodium falciparum* resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. *Antimicrob Agents Chemother* 54: 1949–1954.</jrn>
- <jrn>31. Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, Gadalla A, Mansour F, Warhurst D, El-Sayed BB, Sutherland CJ, 2011. Increased *pfmdr1* copy number and sequence polymorphisms in *Plasmodium falciparum* isolates from Sudanese malaria patients treated with artemether-lumefantrine. *Antimicrob Agents Chemother* 55: 5408–5411.</jrn>
- <jrn>32. Griyovannis A, Niangaly M, Traore OB, Kodio A, Traore K, Tolo Y, Dembele A, Traore A, Bamadio A, Traore ZI, Sanogo K, Sissoko M, Sagara I, Djimde AA, Doumbo OK, 2014. *In vivo* selection of *Plasmodium falciparum* *pfcr* K76 and *pfmdr1* N86 alleles by artemether-lumefantrine in Mali.</jrn>
- <jrn>33. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Bjorkman A, Martensson A, Gil JP, 2013. *Plasmodium falciparum* drug resistance phenotype as assessed by patient antimalarial drug levels and its association with *pfmdr1* polymorphisms. *J Infect Dis* 207: 842–847.</jrn>
- <jrn>34. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F, 2006. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant *Plasmodium falciparum* malaria. *Clin Infect Dis* 42: 1570–1577.</jrn>
- <jrn>35. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O’Neil M, Milhous W, Wirth DF, Oduola AM, 2009. Selection of *Plasmodium falciparum* multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. *Antimicrob Agents Chemother* 53: 888–895.</jrn>
- <jrn>36. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S, 2004. Mefloquine resistance in *Plasmodium falciparum* and increased *pfmdr1* gene copy number. *Lancet* 364: 438–447.</jrn>
- <jrn>37. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA, 2006. Decreasing *pfmdr1* copy number in *Plasmodium falciparum* malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. *J Infect Dis* 194: 528–535.</jrn>
- <jrn>38. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, Yi P, Bouth DM, Bouchier C, Puijalon OM, Meshnick SR, Wongsrichanalai C, Fandeur T, Le BJ, Ringwald P, Arieu F, 2009. *Pfmdr1* copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. *Malar J* 8: 11.</jrn>
- <jrn>39. Mungthin M, Khositnithikul R, Sitthichot N, Suwandittakul N, Wattanaveeradej V, Ward SA, Na-Bangchang K, 2010. Association between the *pfmdr1* gene and *in vitro* artemether and lumefantrine sensitivity in Thai isolates of *Plasmodium falciparum*. *Am J Trop Med Hyg* 83: 1005–1009.</jrn>
- <jrn>40. Simpson JA, Jamsen KM, Anderson TJ, Zaloumis S, Nair S, Woodrow C, White NJ, Nosten F, Price RN, 2013. Nonlinear mixed-effects modelling of *in vitro* drug susceptibility and molecular correlates of multidrug resistant *Plasmodium falciparum*. *PLoS ONE* 8: e69505.</jrn>
- <jrn>41. Ochong EO, van den Broek IV, Keus K, Nzila A, 2003. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the *Plasmodium falciparum* multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. *Am J Trop Med Hyg* 69: 184–187.</jrn>

- <jrn>42. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AM, 2006. Association between mutations in *Plasmodium falciparum* chloroquine resistance transporter and *P. falciparum* multidrug resistance 1 genes and *in vivo* amodiaquine resistance in *P. falciparum* malaria-infected children in Nigeria. *Am J Trop Med Hyg* 75: 155–161.</jrn>
- <jrn>43. Tinto H, Guekoun L, Zongo I, Guiguemde RT, D'Alessandro U, Ouedraogo JB, 2008. Chloroquine-resistance molecular markers (*Pfcr* T76 and *Pfmdr*-1 Y86) and amodiaquine resistance in Burkina Faso. *Trop Med Int Health* 13: 238–240.</jrn>
- <jrn>44. Echeverry DF, Holmgren G, Murillo C, Higuaita JC, Bjorkman A, Gil JP, Osorio L, 2007. Short report: polymorphisms in the *pfcr* and *pfmdr*1 genes of *Plasmodium falciparum* and *in vitro* susceptibility to amodiaquine and desethylamodiaquine. *Am J Trop Med Hyg* 77: 1034–1038.</jrn>
- <jrn>45. Folarin OA, Bustamante C, Gbotosho GO, Sowunmi A, Zalis MG, Oduola AM, Happi CT, 2011. *In vitro* amodiaquine resistance and its association with mutations in *pfcr* and *pfmdr*1 genes of *Plasmodium falciparum* isolates from Nigeria. *Acta Trop* 120: 224–230.</jrn>
- <jrn>46. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ, 2007. Resistance-mediating *Plasmodium falciparum* *pfcr* and *pfmdr*1 alleles after treatment with artesunate-amodiaquine in Uganda. *Antimicrob Agents Chemother* 51: 3023–3025.</jrn>
- <jrn>47. Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A, 2007. Selection of *pfmdr*1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. *Infect Genet Evol* 7: 562–569.</jrn>
- <jrn>48. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A, 2006. Amodiaquine resistant *Plasmodium falciparum* malaria *in vivo* is associated with selection of *pfcr* 76T and *pfmdr*1 86Y. *Infect Genet Evol* 6: 309–314.</jrn>
- <jrn>49. Djimde AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouologuem D, Dicko A, Doumbo OK, 2008. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. *Am J Trop Med Hyg* 78: 455–461.</jrn>
- <jrn>50. Danquah I, Coulibaly B, Meissner P, Petruschke I, Muller O, Mockenhaupt FP, 2010. Selection of *pfmdr*1 and *pfcr* alleles in amodiaquine treatment failure in north-western Burkina Faso. *Acta Trop* 114: 63–66.</jrn>
- <jrn>51. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, Greenwood BM, Warhurst DC, 1997. Evidence for selection for the tyrosine-86 allele of the *pfmdr* 1 gene of *Plasmodium falciparum* by chloroquine and amodiaquine. *Parasitol.* 114: 205–211.</jrn>
- <jrn>52. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC, 2000. The tyrosine-86 allele of the *pfmdr*1 gene of *Plasmodium falciparum* is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. *Mol Biochem Parasitol* 108: 13–23.</jrn>
- <eref>53. WWARN, 2012. *Clinical Module: Data Management and Statistical Analysis Plan. Version 1.2*. Available at: <http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf>. Accessed March 31, 2014.</eref>
- <eref>54. WWARN, 2012. *Statistical Analysis Plan AL Dose Impact Study Group Version 1.9*. Available at: <http://www.wwarn.org/sites/default/files/ALDoseImpactStudyGroupSAP.pdf>. Accessed March 31, 2014.</eref>
- <bok>55. World Health Organization, 2008. *Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations*. Geneva: World Health Organization.</bok>

- <eref>56. WWARN, 2012. *Molecular Module: Data Management and Statistical Analysis Plan. Version 1.0*. Available at: <http://www.wwarn.org/sites/default/files/MolecularDMSAP.pdf>. Accessed March 31, 2014.</eref>
- <eref>57. WWARN, 2012. *Statistical Analysis Plan ASAQ/AL Molecular Marker Study Group. Version 1.0*. Available at: <http://www.wwarn.org/sites/default/files/ASAQALMolecularMarkerStudyGroupSAP.pdf>. Accessed March 31, 2014.</eref>
- <jrn>58. Schoenfeld D, 1982. Partial residuals for the proportional hazards regression model. *Biometrika* 69: 239–241.</jrn>
- <jrn>59. Choudhury J, 2002. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. *Stat Med* 21: 1129–1144.</jrn>
- <jrn>60. Ezzet F, van Vudt M, Nosten F, Looareesuwan S, White NJ, 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. *Antimicrob Agents Chemother* 44: 697–704.</jrn>
- <jrn>61. Duah N, Matrevi S, de Souza D, Binnah D, Tamakloe M, Opoku V, Onwona C, Narh C, Quashie N, Abuaku B, Duplessis C, Kronmann K, Koram K, 2013. Increased *pfmdr1* gene copy number and the decline in *pfert* and *pfmdr1* resistance alleles in Ghanaian *Plasmodium falciparum* isolates after the change of anti-malarial drug treatment policy. *Malar J* 12: 377.</jrn>
- <jrn>62. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F, Miller RS, Meshnick SR, 2003. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in *pfmdr1*. *Antimicrob Agents Chemother* 47: 2418–2423.</jrn>
- <jrn>63. Arieu F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale J-C, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D, 2014. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature* 505: 50–55.</jrn>
- <jrn>64. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kanya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ, 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on *P. falciparum* polymorphisms that modulate drug sensitivity in Ugandan children. *J Infect Dis* 2014 Apr 8 [Epub ahead of print].</jrn>
- <jrn>65. Taylor SM, Juliano JJ, 2014. Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot. *J Infect Dis* 2014 Apr 8 [Epub ahead of print].</jrn>
- <jrn>66. Boni MF, Smith DL, Laxminarayan R, 2008. Benefits of using multiple first-line therapies against malaria. *Proc Natl Acad Sci USA* 105: 14216–14221.</jrn>
- <bok>67. Shretta R, 2008. *Operational Challenges of Implementing Multiple First-Line Therapies for Malaria in Endemic Countries*. Arlington, VA: Management Sciences for Health.</bok>
- <jrn>68. Sutherland CJ, Babiker H, Mackinnon MJ, Ranford-Cartwright L, El Sayed BB, 2011. Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases? *Parasitol.* 138: 1459–1468.</jrn>

FIGURE 1. Patient flow chart for study of parasite risk factors that affect treatment outcomes for *Plasmodium falciparum* malaria after treatment with artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ).

FIGURE 2. Polymerase chain reaction–adjusted efficacy as assessed by Kaplan-Meier survival estimates for artemether-lumefantrine (AL) by *Plasmodium falciparum* multidrug resistance 1 (*pfmdr1*) genotype of initial parasites. Dotted line indicates World Health Organization–recommended 90% efficacy cutoff value for antimalarial drugs. Clinical response of patients with parasites that carry **A**, *pfmdr1* 86Y (blue) versus 86N or N/Y (red); n = 2,543 patients at risk and **B**, *pfmdr1* copy number > 1 (yellow) versus single copy (green); n = 808 patients. This figure appears in color at www.ajtmh.org.

FIGURE 3. **A**, Cumulative (left panels) and relative (right panels) risks of polymerase chain reaction (PCR)–adjusted reinfection for baseline *Plasmodium falciparum* chloroquine resistance transporter (*pfcr*) and *P. falciparum* multidrug resistance 1 (*pfmdr1*) genotypes after artemether-lumefantrine treatment, in which recrudescence and re-infections with other genotypes were treated as competing events. **B**, Cumulative (left panels) and relative (right panels) risks of PCR-adjusted re-infection for baseline *pfcr* and *pfmdr1* genotypes after artesunate-amodiaquine treatment, in which recrudescence and re-infections with other genotypes were treated as competing events. This figure appears in color at www.ajtmh.org.

TABLE 1

Multivariable risk factors for PCR-adjusted recrudescence infections for persons treated with artemether-lumefantrine and artesunate-amodiaquine at day 42*

Treatment and variable	Adjusted HR [95% CI]	P
AL (n = 14,679; 371 recrudescences)		
Age category: ≥ 12 years (reference)		
< 1	1.55 (0.86–2.78)	0.150
1 to < 5	2.38 (1.51–3.75)	< 0.001
5 to < 12	1.39 (0.86–2.23)	0.160
Enrollment parasite density (log scale)	1.13 (1.05–1.23)	0.002
Lumefantrine dose (mg/kg)	1.00 (0.99–1.01)	0.860
ASAQ (n = 7,652; 220 recrudescences)		
Age category: ≥ 12 years (reference)		
< 1	2.20 (1.01–4.78)	0.047
1 to < 5	2.27 (1.13–4.55)	0.021
5 to < 12	1.51 (0.72–3.17)	0.140
Enrollment parasite density (log scale)	1.50 (1.16–1.93)	0.002
Amodiaquine dose (mg/kg)	0.92 (0.82–1.04)	0.180
Drug formulation: fixed dose (reference)		
Co-blistered	0.98 (0.41–2.32)	0.960
Loose	2.94 (1.58–5.48)	0.001

* Risk factors were selected based upon previous analysis of the same data set (“The effect of dosing strategies on the antimalarial efficacy of artemether-lumefantrine: a pooled analysis of individual patient data, by the WWARN AL Study Group” presubmission approved at PLoS Medicine, March 28, 2014 and “The Effect of Dosing Strategies on the Therapeutic Efficacy of Artesunate Amodiaquine for uncomplicated malaria: A Pooled Analysis of Individual Patient Data” presubmission planned for PLoS Medicine before April 15, 2014). Values in bold are statistically significant. PCR = polymerase chain reaction; HR = hazards ratio; CI = confidence interval; AL = artemether-lumefantrine; ASAQ = artesunate-amodiaquine.

TABLE 2

PCR-adjusted adequate clinical and parasitologic response for patients treated with of artemether-lumefantrine and artesunate-amodiaquine after 42 days of follow-up*

Variable	AL	ASAQ fixed dose and co-blistered	ASAQ loose
No. at risk	4,763	1,113	986
ACPR by group, % (95% CI)			
Age category, years			
< 1	96.7 (92.7–98.5)	100	85.2 (70.5–93.0)
1 to < 5	93.6 (92.0–94.8)	96.4 (93.2–98.1)	93.8 (90.0–96.2)
5–12	96.3 (94.5–97.5)	98.8 (91.6–99.8)	99 (96.1–99.8)
≥ 12	95.2 (93.8–96.3)	–	–
Region			
Asia/Oceania	95.2 (93.8–96.2)	–	–
East Africa	93.8 (92.4–95.0)	100†	91.2 (88.0–94.7)
West Africa	96.2 (94.6–97.3)	96.9 (94.2–98.3)	99.2 (96.8–99.8)†
Overall	94.8 (94.0–95.5)	97.0 (94.4–98.4)	93.0 (89.2–95.6)

* PCR = polymerase chain reaction; ACPR = adequate clinical and parasitologic response; AL = artemether-lumefantrine; ASAQ = artesunate –amodiaquine; CI = confidence interval.

† Followed-up to day 28.

TABLE 3

Baseline (pre-treatment) prevalence of genetic markers associated with drug resistance*

Marker	Asia/Oceania	East Africa	West Africa
<i>pfprt</i> 76			
Sample size	84	1,708	1,848
K	3 (4)	553 (32)	494 (27)
K/T	2 (2)	125 (7)	249 (13)
T	79 (94)	1,030 (60)	1105 (60)
<i>pfprt</i> 72–76			
Sample size	84	155	84
CVMNK	3 (4)	37 (24)	14 (17)
CVIET	0	117 (75)	53 (63)
SVMNT	79 (94)	0	0
Mixed	2 (2)	1 (1)	17 (20)
<i>pfmdr1</i> 86			
Sample size	226	2,033	1,321
N	160 (71)	759 (37)	678 (51)
N/Y	0	378 (19)	190 (14)
Y	66 (29)	896 (44)	453 (34)
<i>pfmdr1</i> 184			
Sample size	228	1,275	686
Y	183 (80)	803 (63)	287 (42)
Y/F	8 (4)	130 (10)	77 (11)
F	37 (16)	342 (27)	322 (47)
Sample size	77	1,017	687
D	67 (87)	454 (45)	526 (77)
D/Y	10 (13)	309 (30)	86 (13)
Y	0	254 (25)	75 (11)
<i>pfmdr1</i> 86 + 1246			
Sample size	69	1,000	685
N D	12 (17)	129 (13)	263 (38)
N Y	0	9 (1)	2 (0)
Y D	50 (72)	248 (25)	199 (29)
Y Y	0	220 (22)	71 (10)
Mixed	7 (10)	394 (39)	150 (22)
<i>pfmdr1</i> copy number			
Sample size	176	659	0
1	88 (50)	642 (98)	0
2	57 (32)	16 (2)	0
> 2	31 (18)	1 (0)	0

* Values are no. (%). *pfprt* = *Plasmodium falciparum* chloroquine resistance transporter gene; *pfmdr1* = *P. falciparum* multidrug resistance 1 (*pfmdr1*) gene.

TABLE 4

Multivariable risk factors for PCR-adjusted recrudescence infections of persons treated with artemether-lumefantrine on day 42*

Marker and variable	Adjusted hazard ratio (95% CI)	P
<i>pfmdr1</i> 86 (n = 2,543; 135 recrudescence infections)†		
<i>pfmdr1</i> N86 or N/Y		
In recrudescence up to day 14	0.79 (0.25–2.54)	0.694
In recrudescence between days 14 and 28	4.74 (2.29–9.78)	< 0.001
In recrudescence after day 28	0.84 (0.43–1.66)	0.624
Enrollment parasite density (log _e – scale)	1.13 (0.99–1.29)	0.056
Age category (reference < 1 year)		
1 to < 5	1.05 (0.40–2.75)	0.922
5 to < 12	0.85 (0.30–2.38)	0.752
≥ 12	0.77 (0.25–2.36)	0.647
Lumefantrine dose (mg/kg)	0.99 (0.98–1.00)	0.109
<i>pfmdr1</i> copy number (n = 808; 73 recrudescence infections)		
<i>pfmdr1</i> copy number > 1‡		
In recrudescence up to day 14	83.56 (7.43–939.70)	< 0.001
In recrudescence between days 14 and 21	18.54 (7.61–45.19)	< 0.001
In recrudescence after day 21	0.61 (0.25–1.51)	0.286
Region (reference Africa)		
Asia/Oceania	5.09 (1.06–24.38)	0.042
Enrollment parasite density (log _e – scale)	1.00 (0.85–1.18)	0.978
Age category (reference < 5 years)		
5 to < 12	0.62 (0.22–1.77)	0.368
≥ 12	0.56 (0.16–1.93)	0.359
Lumefantrine dose (mg/kg)	0.98 (0.96–1.00)	0.113
<i>pfmdr1</i> 86 and copy number (n = 719; 59 recrudescence infections)§		
<i>pfmdr1</i> N86 or N/Y		
In recrudescence up to day 14	1.00 (0.07–13.64)	0.997
In recrudescence between days 14 and 28	5.98 (1.68–21.36)	0.006
In recrudescence after day 28	0.51 (0.18–1.47)	0.21
<i>pfmdr1</i> copy number > 1		
In recrudescence up to day 14	2.17 (0.16–29.77)	0.561
In recrudescence between days 14 and 21	6.52 (2.36–17.97)	< 0.001
In recrudescence after day 21	0.94 (0.31–2.82)	0.916
Enrollment parasite density (log _e – scale)	1.08 (0.92–1.28)	0.348
Age category (reference < 5 years)		
5 to < 12	1.46 (0.59–3.57)	0.413
≥ 12	0.79 (0.27–2.33)	0.663
Lumefantrine dose (mg/kg)	0.98 (0.95–1.00)	0.05

* Values in bold are statistically significant. PCR = polymerase chain reaction; CI = confidence interval; *pfmdr1* = *P. falciparum* multidrug resistance 1 (*pfmdr1*) gene.

† Region not included as a covariate or interaction term with *pfmdr1* 86 genotype because proportional hazards assumption was not met.

‡ Sparse data for *pfmdr1* copy number in Africa prevented the inclusion of region as an interaction term.

§ Region as a covariate and region-genotype interaction terms did not have statistically significant effects in this model.

TABLE 5

Selection of *pfprt* and *pfmdr1* genotypes after treatment with artemether-lumefantrine and artesunate-amodiaquine*

Marker	Genotype	Recurrence		Recrudescence		Re-infection	
		AL	ASAQ	AL	ASAQ	AL	ASAQ
<i>pfprt</i> 76	K → T†	16% (89/571)	10% (25/237)	5% (4/73)	20% (7/35)	17% (82/493)	9% (17/196)
	T → K	30% (171/571)	8% (18/237)	25% (18/73)	11% (4/35)	31% (152/493)	7% (14/196)
	No change	54% (311/571)	82% (194/237)	70% (51/73)	69% (24/35)	53% (259/493)	84% (165/196)
		< 0.001	0.286	0.004 (exact)	0.366	< 0.001	0.590
<i>pfmdr1</i> 86	N → Y	13% (95/712)	27% (92/341)	10% (10/101)	18% (5/28)	14% (85/609)	28% (87/308)
	Y → N	40% (286/712)	16% (54/341)	31% (31/101)	14% (4/28)	42% (255/609)	16% (49/308)
	No change	46% (331/712)	57% (195/341)	59% (60/101)	68% (19/28)	44% (269/609)	56% (172/308)
		< 0.001	0.002	0.001	0.739	< 0.001	0.001
<i>pfmdr1</i> 184	Y → F	24% (74/311)	12% (37/303)	20% (14/69)	12% (3/25)	25% (60/242)	12% (34/273)
	F → Y	16% (51/311)	17% (50/303)	14% (10/69)	4% (1/25)	17% (41/242)	18% (49/273)
	No change	60% (186/311)	71% (216/303)	65% (45/69)	84% (21/25)	58% (141/242)	70% (190/273)
		0.040	0.163	0.414	0.625	0.059	0.100
<i>pfmdr1</i> 1246	D → Y	14% (38/273)	32% (102/317)	11% (5/44)	39% (11/28)	15% (33/227)	32% (90/284)
	Y → D	32% (86/273)	19% (60/317)	30% (13/44)	14% (4/28)	32% (73/227)	20% (56/284)
	No change	54% (149/273)	49% (155/317)	59% (26/44)	46% (13/28)	53% (121/227)	48% (138/284)
		< 0.001	0.001	0.059	0.119	< 0.001	0.005
<i>pfmdr1</i> copy number	1 → 2 or more	1% (2/269)	–	4% (2/53)	–	0	–
	2 or more → 1	1% (3/269)	–	2% (1/53)	–	1% (2/216)	–
	No change	98% (264/269)	–	94% (50/53)	–	99% (214/216)	–
		1.000 (exact)		1.000 (exact)		0.500 (exact)	

* Values in bold indicate statistically significant selection ($P < 0.05$) by using McNemar's paired test. Those marked exact were tested by using the exact distribution for small sample sizes. A small number of recurrent infections (4 for AL and 6 for ASAQ) were not polymerase chain reaction-adjusted and were excluded from the analysis of recrudescence and re-infections. *pfprt* = *Plasmodium falciparum* chloroquine resistance transporter gene; *pfmdr1* = *P. falciparum* multidrug resistance 1 (*pfmdr1*) gene; AL = artemether-lumefantrine; ASAQ = artesunate –amodiaquine.

† Each category includes all changes from one allele to another. For example, K → T includes K → T, K → K/T, and K/T → T changes.

SUPPLEMENTAL TABLE 1

Univariable and multivariable risk factors for PCR-adjusted recrudescence at day 42 (n = 14,679 and 371 recrudescences) for patients treated with artemether-lumefantrine*

Variable	No.	Univariate analysis		Multivariate analysis		Population attributable risk†	
		Crude HR (95% CI)	P	Adjusted HR (95% CI)	P	Frequency	PAR
Age (years)	14,679	0.96 (0.94–0.98)	< 0.001	–	–	–	–
Weight (kg)	14,769	0.98 (0.97–0.99)	< 0.001	–	–	–	–
Lumefantrine dose (mg/kg)	14,769	1 (0.99–1)	0.550	1 (0.99–1.01)	0.860	28.13%	2.26%
Clinical variables							
Baseline parasitemia (log scale)	14,769	1.15 (1.07–1.25)	< 0.001	1.13 (1.05–1.23)	0.002	9.12%	4.15%‡
Baseline parasitemia > 100,000/μL	14,769	1.55 (1.15–2.09)	0.004	–	–	–	–
Baseline gametocytemia	7,659	1.55 (1.04–2.32)	0.031	–	–	–	–
Age category	14,679						
≥ 12 years (reference)							
< 1		1.74 (1.01–3)	0.045	1.55 (0.86–2.78)	0.150	9.01%	5.68%
1 to < 5		2.69 (1.73–4.17)	< 0.001	2.38 (1.51–3.75)	< 0.001	45.72%	41.24%‡
5 to < 12		1.51 (0.95–2.38)	0.079	1.39 (0.86–2.23)	0.160	20.63%	9.21%
Weight category	14,769						
≥ 35 kg (reference)							
5 to < 15		2.47 (1.58–3.88)	< 0.001	–	–	–	–
15 to < 25		1.92 (1.21–3.04)	0.005	–	–	–	–
25 to < 35		1.39 (0.75–2.56)	0.300	–	–	–	–
Supervision	14,396						
Full (reference)				–	–	–	–
Partial		0.92 (0.51–1.67)	0.790	–	–	–	–
Unsupervised		1.66 (0.56–4.93)	0.370	–	–	–	–
Co-administration with fat	7,180			–	–	–	–
With fatty meal (reference)							
Without fatty meal		0.91 (0.32–2.61)	0.860	–	–	–	–

* Values in bold are statistically significant. PCR = polymerase chain reaction; HR = hazards ratio; CI = confidence interval; PAR population attributable risk.

† Overall PAR for model: 52.9% calculated as $1 - \prod_{r=1}^R (1 - PAR_r)$

‡ Cumulative PAR for hyper-parasitemia and age 1 to < 5 years: 43.7.

SUPPLEMENTAL TABLE 2

Univariable and multivariable risk factors for PCR-adjusted recrudescence at day 42 (n = 7,652 and 220 recrudescences for final model) for patients treated with artesunate-amodiaquine*

Variable	No. (no.)†	Univariable analysis		Multivariable analysis		PAR‡	
		Crude HR (95% CI)	P	Adjusted HR (95% CI)	P	Frequency	PAR
Amodiaquine dose (mg/kg) (5 units)	7,652 (220)	0.90 (0.8–1.01)	0.081	0.92 (0.82–1.04)	0.180	–	–
Clinical variables							
Parasitemia (log scale)	8,224 (223)	1.53 (1.19–1.97)	< 0.001	1.5 (1.16–1.93)	0.002	10.7%	5.5%
Pfmicl > 100,000/μL	8,224 (223)	1.54 (1.03–2.30)	0.034	–	–	–	–
Baseline fever (temperature > 37.5°C)	7,847 (212)	0.87 (0.64–1.20)	0.400	–	–	–	–
Baseline hemoglobin level	5,708 (193)	0.93 (0.86–1.00)	0.054	–	–	–	–
Baseline anemia (hemoglobin level < 10)	5,708 (193)	1.37 (1.00–1.89)	0.050	–	–	–	–
Baseline gametocyte level	4,258 (91)	1.41 (0.76–2.59)	0.270	–	–	–	–
Species at enrollment							
Pure <i>P. falciparum</i> infection (reference)	8,189 (220)						
Mixed infections	35 (3)	1.28 (0.37–4.41)	0.700	–	–	–	–
Sex							
F (reference)	3,755 (106)						
M	4,308 (102)	0.87 (0.66–1.15)	0.340	–	–	–	–
Age category							
≥ 12 yrs (reference)	1,289 (14)						
< 1	693 (32)	3.52 (1.65–7.5)	0.001	2.2 [1.01–4.78]	0.047	8.4%	11.1%
1 to < 5	4,816 (158)	3.48 (1.78–6.82)	< 0.001	2.27 [1.13–4.55]	0.021	58.5%	46.9%
5 to < 12	1,426 (19)	1.72 (0.84–3.54)	0.140	1.51 [0.72–3.17]	0.280	–	–
Drug formulation							
FDC (reference)	4,212 (78)						
nFDC co-blistered	900 (11)	1.19 (0.51–2.78)	0.700	0.98 [0.41–2.32]	0.960	–	–
nFDC loose	3,112 (134)	3.00 (1.64–5.50)	< 0.001	2.94 [1.58–5.48]	0.001	36.3%	41.9%
Treatment supervision							
Fully (reference)	6,287 (74)						
Partial	1,937 (149)	2.08 (0.79–5.46)	0.140	–	–	–	–

* Values in bold are statistically significant. PCR = polymerase chain reaction; HR = hazards ratio; CI = confidence interval; FDC = fixed-dose combination.

† No. = number of patients (No.); no. = number of PCR-confirmed treatment failures.

‡ Overall PAR for the model accounted by significant variables: 74.0% calculated as $1 - \prod_{r=1}^R (1 - PAR_r)$. For PAR calculation, parasitemia was categorized at 100,000/μL. Variance of the random effect = 0.914. Anemia was not kept for multivariable analysis because of missing values. The coefficients for other covariates remain unaffected with or without anemia in the model. The assumption of proportional hazard held true for overall final multivariable model globally ($P = 0.584$) and individually for each of the covariates ($P > 0.05$).

SUPPLEMENTAL TABLE 3

Summary of studies included in the analysis*

Region, country	Reference	Study year(s)	Treatment (no.)		Transmission zone (no.)		
			AL	ASAQ	High	Moderate	Low
East Africa							
Ethiopia	67	2006	34				34
Ethiopia	68	2008–2009	348				348
Kenya	Unpublished	2007-2008		54			54
Kenya	69	2005	241		241		
Kenya	15	2007		103		103	
Madagascar	70	2006–2007		17	1	15	1
Sudan	31	2006	91				91
Sudan	16	2003		80			80
Tanzania	71	2007–2008	359		359		
Tanzania	11	2007	244		244		
Tanzania	72	2010	108			108	
Tanzania (Zanzibar)	47	2002–2003		208		208	
Tanzania (Zanzibar)	27	2002–2003	200			200	
Tanzania (Zanzibar)	25	2002–2003	†			†	
Tanzania	73	2004	50		50		
Uganda	74	2004–2007	149	149		298	
Uganda	26	2005	204		204		
Uganda	46	2005		204	204		
Uganda	Unpublished	2007–2008	112		112		
West Africa							
Benin	Unpublished	2007	96	95		191	
Burkina Faso	30	2006	188			188	
Burkina Faso	Unpublished	2004–2006		890	890		
Burkina Faso	75	2005	261			261	
Guinea-Bissau	76	2006–2008	191			191	
Liberia	77	2009	150	149	299		
Mali		2009	337		188	77	72
Mali	49	2002–2004		252	252		
Nigeria	78	2007–2008	47	45	92		
Oceania							
Papua New Guinea	79	2005–2007	176			176	
Asia							
Thailand	34	1995–2002	1,417				1,417
Thailand	29	1995–2002	†				†
Total			5,003	2,246	3,136	2,016	2,097

* AL = artemether-lumefantrine; ASAQ = artesunate-amodiaquine.

† Samples overlap with previous study.

SUPPLEMENTAL TABLE 4

Baseline characteristics of patients treated with artemether-lumefantrine or artesunate-amodiaquine*

Treatment, variable	Asia/Oceania	East Africa	West Africa	Overall
AL				
No. (%)	1,593 (31.9)	2,140 (42.8)	1,270 (25.3)	5,003
Study period	1995–2007	2002–2010	2003–2009	1995–2010
Follow-up (days)				
28	19.5%	32.6%	50.8%	33.0%
42	56.2%	39.3%	49.2%	47.2%
43–63	24.4%	28.0%		19.7%
Median age (IQR, range) (years)	18 (10–30, 0.8–70)	3 (2–5, 0.3–81)	4 (3–7, 0.3–61)	5 (3–14, 0.3–81)
< 1	0.1%	7.7%	3.4%	4.2%
1 to < 5	12.1%	59.9%	47.7%	41.6%
5–11	17.4%	18.6%	38.3%	23.2%
≥ 12	70.5%	13.6%	9.7%	30.7%
Missing	0.0%	0.3%	0.9%	0.4%
Baseline parasites/μL geometric mean (95% CI)	5,371 (4,833–5,969)	14,094 (13,015–15,262)	25,066 (23,411–26,838)	12,086 (11,459–12,748)
Supervision				
Full	64.6%	35.8%	62.2%	51.7%
Partial	11.0%	44.4%	34.1%	31.2%
Unsupervised	0.0%	19.8%	0.0%	8.5%
Not stated/unknown	24.4%	0.0%	3.7%	8.7%
Co-administration				
With food	11.0%	20.7%	26.9%	19.2%
Advised to consume fatty food	0.0%	46.0%	0.0%	19.7%
None	0.0%	9.5%	0.0%	4.1%
Not stated	89.0%	23.7%	73.1%	57.0%
ASAQ				
No. (%)		815 (36.3%)	1,431 (63.7%)	2,246
Study period		2002–2008	2002–2009	2002–2009
Follow-up, days				
28		74.5%	82.9%	79.9%
42		25.5%	17.1%	20.1%
Median age (IQR, range) (years)		3 (2–5, 0.4–60)	3 (2–4, 0.4–38)	3 (2–4, 0.4–60)
< 1		8.3%	7.7%	7.9%
1 to < 5		65.3%	78.6%	73.8%
5–11		19.1%	12.6%	15.0%
≥ 12		7.0%	1.0%	3.2%
Missing		0.2%	0.0%	0.1%

Baseline parasites/μL geometric mean (95% CI)		18,412 (16,480–20,569)	15,661 (14,593–16,806)	16,608 (15,635–17,642)
Formulation				
Fixed dose		3.2%	48.1%	31.8%
Non-fixed dose		94.7%	51.9%	67.4%
Supervision				
Full		63.8%	62.2%	62.8%
Partial			17.1%	10.9%
Not stated/unknown		36.2%	20.8%	26.4%

* AL = artemether-lumefantrine; IQR = interquartile range; CI, confidence interval; ASAQ = artesunate-amodiaquine.

Figure 1




Figure 2




Figure 3a




Figure 3b

